PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Revenue and Earnings Performance - PTC Therapeutics reported $196.79 million in revenue for Q3 2024, a 0.1% year-over-year increase [1] - The revenue figure exceeded the Zacks Consensus Estimate of $173.51 million by 13.41% [1] - EPS for the quarter was -$1.39, an improvement from -$1.76 in the same period last year [1] - The EPS result was 9.74% better than the consensus estimate of -$1.54 [1] Key Revenue Metrics - Net product revenue was $135.42 million, 6% lower year-over-year but 21.7% above the six-analyst average estimate of $111.28 million [3] - Royalty revenue reached $61.37 million, a 22.3% year-over-year increase, slightly below the six-analyst estimate of $62.95 million [3] - Emflaza net product revenue was $52 million, 22.4% lower year-over-year but 41% above the four-analyst estimate of $36.89 million [3] - Translarna net product revenue stood at $72 million, 4.4% higher year-over-year and 10.3% above the four-analyst estimate of $65.30 million [3] Stock Performance - PTC Therapeutics shares gained 8.1% over the past month, outperforming the Zacks S&P 500 composite's 3.2% increase [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting potential performance in line with the broader market [4]